Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 1
1985 3
1986 6
1987 1
1988 3
1989 8
1990 4
1991 13
1992 33
1993 51
1994 101
1995 75
1996 88
1997 65
1998 65
1999 73
2000 74
2001 57
2002 78
2003 70
2004 100
2005 68
2006 74
2007 60
2008 56
2009 72
2010 96
2011 97
2012 77
2013 74
2014 76
2015 85
2016 63
2017 82
2018 91
2019 104
2020 140
2021 24
Text availability
Article attribute
Article type
Publication date

Search Results

2,135 results
Results by year
Filters applied: . Clear all
Page 1
Cladribine: mechanisms and mysteries in multiple sclerosis.
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Jacobs BM, et al. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1266-1271. doi: 10.1136/jnnp-2017-317411. Epub 2018 Jul 10. J Neurol Neurosurg Psychiatry. 2018. PMID: 29991490 Review.
The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. ...CONCLUSIONS: Cladribine is a safe and effective form of induction therapy for relapsing MS. ...
The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. ...CONCLUSIONS: Cladribine is a safe …
Cladribine Tablets: A Review in Relapsing MS.
Deeks ED. Deeks ED. CNS Drugs. 2018 Aug;32(8):785-796. doi: 10.1007/s40263-018-0562-0. CNS Drugs. 2018. PMID: 30105527 Free PMC article. Review.
Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS) pathogenesis. Cladribine tablets (Mavenclad()) represent the first short-course oral disease-modifying drug (DMD) for use in MS. ..
Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS
Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
Giovannoni G. Giovannoni G. Neurotherapeutics. 2017 Oct;14(4):874-887. doi: 10.1007/s13311-017-0573-4. Neurotherapeutics. 2017. PMID: 29168160 Free PMC article. Review.
An oral formulation of cladribine has been developed to be given as short courses over two annual cycles. ...Oral cladribine is effective in relapsing forms of multiple sclerosis. As a selective immune reconstitution therapy (SIRT), cladribine acts as a short …
An oral formulation of cladribine has been developed to be given as short courses over two annual cycles. ...Oral cladribine i …
Cladribine (Mavenclad) for multiple sclerosis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Jul 29;61(1577):118-120. Med Lett Drugs Ther. 2019. PMID: 31381552 Review. No abstract available.
Potential mechanisms of action related to the efficacy and safety of cladribine.
Baker D, Pryce G, Herrod SS, Schmierer K. Baker D, et al. Mult Scler Relat Disord. 2019 May;30:176-186. doi: 10.1016/j.msard.2019.02.018. Epub 2019 Feb 14. Mult Scler Relat Disord. 2019. PMID: 30785074 Review.
Oral cladribine is a novel treatment for relapsing multiple sclerosis (MS). ...These concepts are relatively simple to interrogate, and can be modified as new knowledge about the durability of disease control and safety with cladribine emerges....
Oral cladribine is a novel treatment for relapsing multiple sclerosis (MS). ...These concepts are relatively simple to interrogate, a …
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
BACKGROUND: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. ...CONCLUSIONS: Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 …
BACKGROUND: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. ...CONCLUSIONS: Treatment with …
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F. Comi G, et al. Mult Scler Relat Disord. 2019 Apr;29:168-174. doi: 10.1016/j.msard.2019.01.038. Epub 2019 Jan 24. Mult Scler Relat Disord. 2019. PMID: 30885375 Free article.
RESULTS: Treatment with cladribine tablets 3.5 mg/kg resulted in selective reductions in B and T lymphocytes. ...CONCLUSION: These results show the dynamics of lymphocyte count changes following treatment with cladribine tablets 3.5 mg/kg. The immune cell repopulati …
RESULTS: Treatment with cladribine tablets 3.5 mg/kg resulted in selective reductions in B and T lymphocytes. ...CONCLUSION: These re …
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E. Cook S, et al. Mult Scler Relat Disord. 2019 Apr;29:157-167. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20. Mult Scler Relat Disord. 2019. PMID: 30885374 Free article.
To better characterize rare events, additional data from earlier studies which involved the use of parenteral cladribine in patients with MS, and the ONWARD study, in which patients were given cladribine tablets in addition to interferon (IFN)-beta or placebo plus I …
To better characterize rare events, additional data from earlier studies which involved the use of parenteral cladribine in patients …
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Meuth SG, Bayas A, Kallmann B, Kleinschnitz C, Linker R, Rieckmann P, Mäurer M. Meuth SG, et al. Expert Opin Pharmacother. 2020 Nov;21(16):1965-1969. doi: 10.1080/14656566.2020.1792885. Epub 2020 Jul 13. Expert Opin Pharmacother. 2020. PMID: 32658554 Review.
INTRODUCTION: Oral cladribine is a highly effective pulsed selective immune reconstitution therapy licensed for relapsing multiple sclerosis. ...AREAS COVERED: The long-term management of patients treated with oral cladribine has not been fully defined on the basis …
INTRODUCTION: Oral cladribine is a highly effective pulsed selective immune reconstitution therapy licensed for relapsing multiple sc …
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Chihara D, et al. J Clin Oncol. 2020 May 10;38(14):1527-1538. doi: 10.1200/JCO.19.02250. Epub 2020 Feb 28. J Clin Oncol. 2020. PMID: 32109194 Clinical Trial.
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. ...CONCLUSION: Achieving MRD-free CR of HCL after first-line cladribine is greatly enhanced by concurrent rituximab and less …
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 …
2,135 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page